Comparisons between tumour tissue PIF-CP gene expression and benign tissue expression were tested by linear regression analysis following natural logarithmic transformation of the data.
To identify other relevant factors regarding expression of Dicer, the expression was tested by histology, performance status, tumor differentiation, tumor status, nodal status, and vascular infiltration.
To detail the melanocyte populations expressing the transgene, PAX3 expression was tested by immunohistochemical staining in hair follicles and epidermis of wild-type and PAX3-tg mice.
To identify a clinically meaningful cut-off for Aurora A mRNA expression, various levels of Aurora A mRNA expression were tested by the Kaplan-Meier method and verified by the log-rank test.
In the present report, we have analysed HE4 gene expression levels by quantitative real-time PCR, whereas protein expression was tested by immunohistochemistry on tissue microarrays in a large cohort of EC patients.
Our ability to detect expression of genes by qPCR, most at levels well above background, in 3' amplified samples led us to hypothesize that buccal samples could be used for differential expression testing by microarray analysis.
Currently, estrogen receptor (ER) expression testing by immunohistochemistry (IHC) and human epidermal growth factor receptor 2 (HER2) overexpression by IHC or gene amplification detected by in situ hybridization are the only routinely used biomarkers to select for molecular targeted treatments.
In fact, quantitative c-erbB-2 mRNA expression testing by real-time RT PCR unequivocally identified 10 out of 36 (28%) patients, whose tumours did not exhibit (specificity 100%) a major histopathologic response to the applied preoperative treatment.
While this range may exclude some rare, low-abundant transcripts, it presents a more conservative and reliable approach to differential expression testing by emphasising the accuracy of the assembly rather than the identification of low-abundant transcripts from both treatments.
